Compare Quest Diagnostics Inc (DGX) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Grab Holdings Ltd. — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Grab Holdings Ltd. trades at $3.82 (market cap $15.54B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| DGX | GRAB | |
|---|---|---|
Market Cap | $22.80B | $15.54B |
Sector | Health | Technology |
52-Week High | $216.02 | $6.45 |
52-Week Low | $166.42 | $3.27 |
Enterprise Value | $28.82B | $11.23B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
GRAB trades at $3.94, up 0.25% on the day, with a bullish technical signal and strong analyst support. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from prior losses. Revenue growth continues, reaching $3.37B in 2025. Recent news highlights market outperformance and investor attention, though the stock reacted negatively to Uber CEO's board departure in early July 2026.
Outlook remains positive with 91.67% analyst buy ratings and $5.45 consensus target, implying 38% upside. Key risks include competitive pressures in ride-hailing, execution challenges in expanding financial services, and potential market volatility. Profitability trajectory and cash flow sustainability are critical for maintaining investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
